Trial Profile
A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 12 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 12 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 21 Apr 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.